Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years.
• Able to provide written consent.
• Patient has given permission to give tumor/blood sample for research testing.
• Histological confirmation of squamous cell carcinoma or adenosquamous carcinoma.
• Known HPV status defined as positive staining for p16 on IHC or DNA ISH for HPV.
• Willingness to return to enrolling institution (Mayo Clinic Rochester or the University of Minnesota) for follow-up (during the Active Monitoring Phase of the study) or complete blood draws locally using study mail-in kits.
• Consent to allow blood specimens to be shared with potential external collaborators.
• Definitive Chemoradiotherapy for Locally Advanced Disease (FIGO Stage IB2-IIIC):
  • FIGO 2019 Stage IB2-IIIC or not a surgical candidate;
  • Plan to undergo definitive chemoradiotherapy including external beam radiotherapy, brachytherapy, and chemotherapy.

Exclusion Criteria: 

• Other active malignancy ≤ 2 years prior to registration. 
  • EXCEPTIONS:  Non-melanotic skin cancer.
  • NOTE:  If there is a history or prior malignancy, they must not be receiving other specific treatment for cancer.
• Pregnancy or lactation.
• Inability on the part of the patient to understand the informed consent to be compliant with the protocol.

Eligibility last updated 3/24/22. Questions regarding updates should be directed to the study team contact.